Every woman in pregnancy should be tested for blood grouping determination and antibody screening to identify the Rh status and the presence of an immunization that posese the fetus at risk of hemolytic disease of fetus and newborn (HFDN) also known as erythroblastosis fetalis.
According to the American Academy of Pediatrics (AAP), “if a mother has not had prenatal blood grouping or is Rh- negative, a direct antibody test (or Coombs’ test), blood type, and an Rh (D) type on the infant’s (cord) blood are strongly recommended.”
Blood group and detection of irregular RBC antibodies checked at week 28th of pregnancy. The Rh and ABO statuses of the father of the fetus of a Rh-negative pregnant woman should be determined. If he is heterozygous, the risk of Rh immunization is halved. If the ABO and Rh genotype of the father are known, the risk of Rh immunization can be estimated.
It is important to retest regularly a Rh-negative pregnant woman who has a Rh-positive mate. Further testing should be carried out at weeks 18 to 20 of pregnancy and every 4 weeks thereafter considering that an initial immune response rarely occurs before the week 20 of gestation.

